Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.
Hear Dr. Ulrike von Arnim discuss the expert recommendations for monitoring patients with EoE in routine clinical practice.
Join Dr. Nirmala Gonsalves as she reviews some of the tools to assess quality-of-life outcomes in patients with EoE.

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the importance of an interdisciplinary team for EoE management.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the value of different aspects of histology beyond eosinophil count and the importance of multidimensional assessment of EoE

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares highlights the substantial impact of type 2 inflammatory diseases on the quality of life of patients and their caregivers.
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.
This chapter focuses on the importance of shared decision-making and regular, long-term monitoring of histology and endoscopy, not just symptoms.